Despite recent innovation and continual growth within the digital health technology (DHT) space, DHT organizations still face many challenges on their journey to realize the impact of their solutions. Join us as we welcome experts in the space to discuss the current state of the DHT landscape, strategies for conducting successful clinical trials and how to generate quality evidence on the journey to approval.
During this webinar, a panel of industry experts will...
Dr. Shaheen Lakhan, MD, PhD, FAAN, is an inventive physician-scientist, esteemed biopharma board director, and distinguished biotech executive with 20 years of experience in healthcare, academia, and industry. He is board-certified in both neurology and pain medicine trained at Cleveland Clinic and Massachusetts General Hospital. Passionate about the convergence of science, technology, and medicine, he pioneered several novel therapeutics and clinical service lines to benefit patients in need. As Chief Medical Officer at Click Therapeutics, Dr. Lakhan advances first-in-class treatments via trail-blazing pharma partnerships with Otsuka and Boehringer Ingelheim. He serves as a Board Director at SpineThera, propelling novel drug-delivery platforms for long lasting pain relief. His industry expertise spans biopharma leaders like Sage Therapeutics, Neurocrine, Zogenix, Benuvia Therapeutics, and FSD Pharma, and biotech disruptors like The Learning Corp, Fern Health, and Lin Health.
Dr. Bob Schafer is a neuroscientist, entrepreneur, and business leader. He is CEO of Lumos Labs, a digital health and medicine company focused on brain and cognitive health. Best known for its consumer brain training program, Lumosity, Lumos Labs is now applying an unparalleled real-world data set and 15 years of R&D to the development of digital therapeutics. Prior to Lumos, Dr. Schafer founded Prophecy Sciences, which used cognitive assessments and machine learning methods to predict real-world outcomes related to workplace performance, team chemistry, athleticism and more.
John A. Wagner, M.D., Ph.D., oversees clinical investment and strategy at Koneksa. With more than 20 years of drug development experience, Dr. Wagner has led more than 150 first-in-human studies and has been instrumental in bringing numerous blockbuster programs to market. Prior to joining Koneksa, John was CMO of Cygnal Therapeutics, held senior leadership roles at Takeda and Merck, and was a venture partner at Foresite Capital. In addition, John is editor-in-chief of Clinical and Translational Science and an executive committee member of the Foundation for the National Institutes of Health Biomarkers Consortium.
Nicole Latimer is the Chief Executive Officer of Medrio. As CEO, Nicole carves out her time in three equally and critically important areas: studying the life sciences industry, making decisions about how Medrio can have a greater impact on that industry, and then focusing on the best way to communicate those decisions to staff and customers.
She brings 25 years of impressive and broad-based healthcare experience, including stints at The Advisory Board Company (now part of Optum) and Deloitte Consulting, where she focused on population health management, health system growth strategies, patient and employee education, and SaaS development and delivery. Most recently, in her role as CEO of Staywell, she drove the company’s mission to be the premier provider of lifestyle risk management programs for the entire healthcare ecosystem leveraging behavioral science as the foundation for improving health outcomes. She shines at redesigning processes, increasing efficiency, and reducing costs.